Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 4 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2020 Filed Feb 13, 2020 21:12 UTC |
ASADORIAN RAFFIChief Financial Officer
|
Tax withholdingCommon Stock | 7,924 | $1.71 | $13,550.04 |
DisclosureSEC source: 0001209191-20-009162 · doc4.xml · nonDerivative · entry 1 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,765 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:12 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 23,052 | $1.71 | $39,418.92 |
DisclosureSEC source: 0001209191-20-009161 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,892 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:13 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-007742 · doc4.xml · derivative · entry 2 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2030-02-06 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:13 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007742 · doc4.xml · nonDerivative · entry 1 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,907 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:12 UTC |
Dasu Badri NChief Engineering Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-007741 · doc4.xml · derivative · entry 2 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-06 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:12 UTC |
Dasu Badri NChief Engineering Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007741 · doc4.xml · nonDerivative · entry 1 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,267 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:09 UTC |
ASADORIAN RAFFIChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-007739 · doc4.xml · derivative · entry 2 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2030-02-06 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:09 UTC |
ASADORIAN RAFFIChief Financial Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007739 · doc4.xml · nonDerivative · entry 1 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,689 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:10 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-007740 · doc4.xml · derivative · entry 2 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-02-06 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:10 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007740 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,944 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:08 UTC |
Hamel Lawrence GChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-007738 · doc4.xml · derivative · entry 3 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-06 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the grant date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 06, 2020 Filed Feb 8, 2020 02:08 UTC |
Hamel Lawrence GChief Development Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007738 · doc4.xml · nonDerivative · entry 1 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,382 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 6, 2021, February 6, 2022 and February 6, 2023. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:22 UTC |
EDWARDS MARK GDirector
|
PurchaseCommon Stock | 25,000 | $1.78 | $44,575.00 |
DisclosureSEC source: 0001209191-19-056002 · doc4.xml · nonDerivative · entry 1 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,750 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $1.7741 to $1.80 on November 12, 2019. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 11:07 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 8,379 | $1.79 | $14,973.27 |
DisclosureSEC source: 0000899243-19-027073 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,944 Read SEC document |
| November 02, 2019 Filed Nov 4, 2019 11:05 UTC |
Dasu Badri NChief Engineering Officer
|
GrantStock Option (Right to Buy) · Derivative | 31,625 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026514 · doc4.xml · derivative · entry 1 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,250 Underlying: Common Stock · 31,625 shares Expires 2028-11-02 F1 · derivative.exercise_date: On April 7, 2018, the reporting person was granted a performance-based option to purchase 63,250 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 31,625 shares on that date. On November 2, 2019, the remaining balance of the option vested. Read SEC document |
| November 02, 2019 Filed Nov 4, 2019 11:07 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 47,575 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026515 · doc4.xml · derivative · entry 2 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,150 Underlying: Common Stock · 47,575 shares Expires 2028-11-02 F2 · derivative.exercise_date: On April 7, 2018, the reporting person was granted a performance-based option to purchase 95,150 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 47,575 shares on that date. On November 2, 2019, the remaining balance of the option vested. Read SEC document |
| November 02, 2019 Filed Nov 4, 2019 11:05 UTC |
Hamel Lawrence GChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 26,125 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026513 · doc4.xml · derivative · entry 3 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,250 Underlying: Common Stock · 26,125 shares Expires 2028-11-02 F2 · derivative.exercise_date: On April 7, 2018, the reporting person was granted a performance-based option to purchase 52,250 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares on that date. On November 2, 2019, the remaining balance of the option vested. Read SEC document |
| November 02, 2019 Filed Nov 4, 2019 11:05 UTC |
ASADORIAN RAFFIChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,563 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026512 · doc4.xml · derivative · entry 2 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,125 Underlying: Common Stock · 40,563 shares Expires 2028-11-02 F2 · derivative.exercise_date: On April 7, 2018, the reporting person was granted a performance-based option to purchase 81,125 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 40,562 shares on that date. On November 2, 2019, the remaining balance of the option vested. Read SEC document |
| November 02, 2019 Filed Nov 4, 2019 11:04 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 96,250 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026511 · doc4.xml · derivative · entry 2 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 96,250 shares Expires 2028-11-02 F2 · derivative.exercise_date: On April 7, 2018, the reporting person was granted a performance-based option to purchase 192,500 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 96,250 shares on that date. On November 2, 2019, the remaining balance of the option vested. Read SEC document |
| August 26, 2019 Filed Aug 26, 2019 20:52 UTC |
EDWARDS MARK GDirector
|
PurchaseCommon Stock | 5,000 | $2.17 | $10,849.50 |
DisclosureSEC source: 0001209191-19-047417 · doc4.xml · nonDerivative · entry 2 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,750 Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 20:52 UTC |
EDWARDS MARK GDirector
|
PurchaseCommon Stock | 10,000 | $2.20 | $21,956.00 |
DisclosureSEC source: 0001209191-19-047417 · doc4.xml · nonDerivative · entry 1 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,750 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.185 to $2.20 on August 23, 2019. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 22:58 UTC |
EDWARDS MARK GDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039017 · doc4.xml · derivative · entry 2 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 22:58 UTC |
EDWARDS MARK GDirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039017 · doc4.xml · nonDerivative · entry 1 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:05 UTC |
WAN MARK ADirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039023 · doc4.xml · derivative · entry 2 WAN MARK A · CIK 0001190472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:05 UTC |
WAN MARK ADirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039023 · doc4.xml · nonDerivative · entry 1 WAN MARK A · CIK 0001190472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:03 UTC |
HOFFMAN STEPHEN JDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039020 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:03 UTC |
HOFFMAN STEPHEN JDirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039020 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:04 UTC |
Rosen Howard BDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039022 · doc4.xml · derivative · entry 2 Rosen Howard B · CIK 0001307068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:04 UTC |
Rosen Howard BDirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039022 · doc4.xml · nonDerivative · entry 1 Rosen Howard B · CIK 0001307068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,250 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. F3 · balance_after: Balance includes non-reportable acquisition of 7,500 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:02 UTC |
Afable RichardDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039019 · doc4.xml · derivative · entry 2 Afable Richard · CIK 0001594021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:02 UTC |
Afable RichardDirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039019 · doc4.xml · nonDerivative · entry 1 Afable Richard · CIK 0001594021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:00 UTC |
ADAMS ADRIANDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039018 · doc4.xml · derivative · entry 2 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:00 UTC |
ADAMS ADRIANDirector
|
GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039018 · doc4.xml · nonDerivative · entry 1 ADAMS ADRIAN · CIK 0001248144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 10:02 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 5,000 | $2.31 | $11,550.00 |
DisclosureSEC source: 0000899243-19-015714 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,884 Read SEC document |
| March 12, 2019 Filed Mar 12, 2019 18:15 UTC |
EDWARDS MARK GDirector
|
PurchaseCommon Stock | 19,000 | $2.99 | $56,889.80 |
DisclosureSEC source: 0001209191-19-018711 · doc4.xml · nonDerivative · entry 1 EDWARDS MARK G · CIK 0001190429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.98 to $3.00 on March 12, 2019. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:28 UTC |
ASADORIAN RAFFIChief Financial Officer
|
PurchaseCommon Stock | 3,647 | $2.81 | $10,248.07 |
DisclosureSEC source: 0001209191-19-015634 · doc4.xml · nonDerivative · entry 1 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,397 F1 · balance_after: Balance includes non-reportable acquisition of 3,647 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:26 UTC |
Dasu Badri NChief Engineering Officer
|
PurchaseCommon Stock | 9,206 | $2.81 | $25,868.86 |
DisclosureSEC source: 0001209191-19-015629 · doc4.xml · nonDerivative · entry 1 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,267 F1 · balance_after: Balance includes non-reportable acquisition of 9,206 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:25 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
PurchaseCommon Stock | 3,234 | $2.81 | $9,087.54 |
DisclosureSEC source: 0001209191-19-015622 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,884 F1 · balance_after: Balance includes non-reportable acquisition of 3,234 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:24 UTC |
Hamel Lawrence GChief Development Officer
|
PurchaseCommon Stock | 3,682 | $2.81 | $10,346.42 |
DisclosureSEC source: 0001209191-19-015617 · doc4.xml · nonDerivative · entry 1 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,053 F1 · balance_after: Balance includes non-reportable acquisition of 3,682 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:23 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
PurchaseCommon Stock | 840 | $2.81 | $2,360.40 |
DisclosureSEC source: 0001209191-19-015612 · doc4.xml · nonDerivative · entry 1 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,724 F1 · balance_after: Balance includes non-reportable acquisition of 840 shares of Common Stock through the Company's Employee Stock Purchase Plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:45 UTC |
Hamel Lawrence GChief Development Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-009822 · doc4.xml · derivative · entry 3 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-11 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:45 UTC |
Hamel Lawrence GChief Development Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009822 · doc4.xml · nonDerivative · entry 1 Hamel Lawrence G · CIK 0001511368 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,371 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:44 UTC |
Dasu Badri NChief Engineering Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-009820 · doc4.xml · derivative · entry 2 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-11 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:44 UTC |
Dasu Badri NChief Engineering Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009820 · doc4.xml · nonDerivative · entry 1 Dasu Badri N · CIK 0001310803 · Chief Engineering Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,061 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:43 UTC |
ASADORIAN RAFFIChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-009816 · doc4.xml · derivative · entry 2 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2029-02-11 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:43 UTC |
ASADORIAN RAFFIChief Financial Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009816 · doc4.xml · nonDerivative · entry 1 ASADORIAN RAFFI · CIK 0001628970 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:42 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 137,500 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-009812 · doc4.xml · derivative · entry 2 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 137,500 shares Expires 2029-02-11 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:42 UTC |
Palmer Pamela PDirector · Chief Medical Officer
|
GrantCommon Stock | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009812 · doc4.xml · nonDerivative · entry 1 Palmer Pamela P · CIK 0001511365 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,884 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:40 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001209191-19-009806 · doc4.xml · derivative · entry 2 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-02-11 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:40 UTC |
Angotti Vincent J.Director · Chief Executive Officer
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009806 · doc4.xml · nonDerivative · entry 1 Angotti Vincent J. · CIK 0001700225 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,650 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2020, February 11, 2021 and February 11, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.